Kana Miyazaki

2.1k total citations
46 papers, 403 citations indexed

About

Kana Miyazaki is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Kana Miyazaki has authored 46 papers receiving a total of 403 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Pathology and Forensic Medicine, 17 papers in Oncology and 12 papers in Genetics. Recurrent topics in Kana Miyazaki's work include Lymphoma Diagnosis and Treatment (31 papers), CNS Lymphoma Diagnosis and Treatment (12 papers) and Viral-associated cancers and disorders (9 papers). Kana Miyazaki is often cited by papers focused on Lymphoma Diagnosis and Treatment (31 papers), CNS Lymphoma Diagnosis and Treatment (12 papers) and Viral-associated cancers and disorders (9 papers). Kana Miyazaki collaborates with scholars based in Japan, United States and China. Kana Miyazaki's co-authors include Motoko Yamaguchi, Naoyuki Katayama, Hiroshi Shiku, Hiroshi Imai, Satoshi Tamaru, Ritsuro Suzuki, Tohru Kobayashi, Kazutaka Sunami, Kenichi Ishizawa and Isao Tawara and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Physical Chemistry B.

In The Last Decade

Kana Miyazaki

42 papers receiving 391 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kana Miyazaki Japan 12 285 228 97 95 86 46 403
Sonia González de Villambrosía Spain 10 345 1.2× 307 1.3× 88 0.9× 109 1.1× 63 0.7× 25 444
Ken Ohmachi Japan 13 403 1.4× 342 1.5× 107 1.1× 211 2.2× 91 1.1× 46 599
Jiaqin Yan China 13 338 1.2× 310 1.4× 56 0.6× 60 0.6× 197 2.3× 39 534
Teeraya Puavilai Thailand 8 178 0.6× 142 0.6× 36 0.4× 63 0.7× 80 0.9× 23 322
Lina Odqvist Sweden 6 157 0.6× 150 0.7× 45 0.5× 44 0.5× 92 1.1× 10 290
Akito Dobashi Japan 9 205 0.7× 188 0.8× 37 0.4× 47 0.5× 69 0.8× 18 384
Narittee Sukswai Thailand 8 120 0.4× 124 0.5× 44 0.5× 35 0.4× 48 0.6× 21 282
Fontanet Bijou France 11 234 0.8× 233 1.0× 45 0.5× 217 2.3× 56 0.7× 46 467

Countries citing papers authored by Kana Miyazaki

Since Specialization
Citations

This map shows the geographic impact of Kana Miyazaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kana Miyazaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kana Miyazaki more than expected).

Fields of papers citing papers by Kana Miyazaki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kana Miyazaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kana Miyazaki. The network helps show where Kana Miyazaki may publish in the future.

Co-authorship network of co-authors of Kana Miyazaki

This figure shows the co-authorship network connecting the top 25 collaborators of Kana Miyazaki. A scholar is included among the top collaborators of Kana Miyazaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kana Miyazaki. Kana Miyazaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fujimoto, Ayumi, Kana Miyazaki, Kimikazu Yakushijin, et al.. (2025). Improved prognosis of advanced-stage extranodal NK/T-cell lymphoma: results of the NKEA-Next study. Leukemia. 39(4). 909–916. 1 indexed citations
2.
Yamaguchi, Motoko, Noriko Fukuhara, Jun Takizawa, et al.. (2024). Alemtuzumab monotherapy for T-cell prolymphocytic leukemia: an observational study in Japan. Journal of Clinical and Experimental Hematopathology. 64(3). 216–222.
3.
Fukushima, Takuya, Kunihiro Tsukasaki, Ryunosuke Machida, et al.. (2024). Upfront allo-HSCT after intensive chemotherapy for untreated aggressive ATL: JCOG0907, a single-arm, phase 3 trial.. Journal of Clinical Oncology. 42(16_suppl). 7001–7001. 1 indexed citations
4.
Miyazaki, Kana, Takashi Kikukawa, Masashi Unno, & Tomotsumi Fujisawa. (2024). Chromophore Structural Change during the Photocycle of a Light-Driven Cl– Pump from Mastigocladopsis repens: A Cryogenic Raman Study. The Journal of Physical Chemistry B. 128(40). 9692–9698. 1 indexed citations
5.
Yamamoto, Y., Kentaro Noda, Yasuo Suzuki, et al.. (2022). Subcutaneous Panniculitis-like T-cell Lymphoma with a <i>HAVCR2</i> Mutation Diagnosed after 10 Years of Treatment with Glucocorticoids and Cyclosporine as Lupus Panniculitis. Internal Medicine. 62(10). 1537–1540. 2 indexed citations
6.
Ri, Masaki, Shinsuke Iida, Dai Maruyama, et al.. (2021). HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: An exploratory biomarker study of JCOG1105 (JCOG1105A1). Cancer Science. 112(12). 5011–5019. 3 indexed citations
7.
Miyazaki, Kana, Hiroshi Imai, Eri Nakano, et al.. (2021). Early central nervous system relapse of monomorphic epitheliotropic intestinal T-cell lymphoma after cord blood transplantation. International Journal of Hematology. 114(1). 129–135. 6 indexed citations
8.
Jeong, Hyehyun, Motoko Yamaguchi, Insuk Sohn, et al.. (2020). Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma. Blood. 136(22). 2548–2556. 17 indexed citations
9.
Suzuki, Ritsuro, Tsutomu Takahashi, Youko Suehiro, et al.. (2020). Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data. International Journal of Hematology. 112(6). 807–816. 6 indexed citations
10.
Matsumoto, Takeshi, Kana Miyazaki, Atsushi Fujieda, et al.. (2019). [Atypical hemolytic uremic syndrome with C3 p.I1157T missense mutation successfully treated with eculizumab].. PubMed. 59(2). 178–181. 2 indexed citations
11.
Nakase, Kazunori, Akiko Nakamura, Yumiko Sugawara, et al.. (2017). Management of Pulmonary Mucormycosis Based on a Polymerase Chain Reaction (PCR) Diagnosis in Patients with Hematologic Malignancies: A Report of Four Cases. Internal Medicine. 56(6). 707–711. 15 indexed citations
12.
13.
Takeuchi, Toshifumi, Motoko Yamaguchi, Kyoko Kobayashi, et al.. (2016). MYD88, CD79B, and CARD11 gene mutations in CD5‐positive diffuse large B‐cell lymphoma. Cancer. 123(7). 1166–1173. 17 indexed citations
14.
Miyazaki, Kana. (2016). Treatment of Diffuse Large B-Cell Lymphoma. Journal of Clinical and Experimental Hematopathology. 56(2). 79–88. 48 indexed citations
15.
Miyazaki, Kana, Motoko Yamaguchi, Ritsuro Suzuki, et al.. (2011). CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Annals of Oncology. 22(7). 1601–1607. 90 indexed citations
16.
Miyazaki, Kana, et al.. (2011). An adolescent with marked hyperimmuno-globulinemia E showing minimal change nephrotic syndrome and a STAT3 gene mutation. Clinical Nephrology. 75(4). 369–373. 4 indexed citations
17.
Miyazaki, Kana, Motoko Yamaguchi, Hiroshi Imai, et al.. (2010). Gene Expression Profiling of Diffuse Large B-Cell Lymphomas Supervised by CD5 Expression. Blood. 116(21). 4164–4164. 1 indexed citations
18.
Miyazaki, Kana, Motoko Yamaguchi, Hiroshi Imai, et al.. (2008). Gene expression profiling of peripheral T-cell lymphoma including γδ T-cell lymphoma. Blood. 113(5). 1071–1074. 37 indexed citations
19.
Kimura, Miho, Motoko Yamaguchi, Shigeo Nakamura, et al.. (2007). Clinicopathologic Significance of Loss of CD19 Expression in Diffuse Large B-Cell Lymphoma. International Journal of Hematology. 85(1). 41–48. 7 indexed citations
20.
Tawara, Isao, Satoshi Ueno, Miho Kimura, et al.. (2006). De novo CD5-positive Diffuse Large B-cell Lymphoma of the Temporal Bone Presenting with an External Auditory Canal Tumor. Internal Medicine. 45(11). 733–737. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sonia González de Villambrosía Breakdown of academic impact, for papers by Ken Ohmachi Breakdown of academic impact, for papers by Jiaqin Yan Breakdown of academic impact, for papers by Teeraya Puavilai Breakdown of academic impact, for papers by Lina Odqvist Breakdown of academic impact, for papers by Akito Dobashi Breakdown of academic impact, for papers by Narittee Sukswai Breakdown of academic impact, for papers by Fontanet Bijou
Rankless by CCL
2026